A Study to Evaluate Mezigdomide in Combination With Carfilzomib and Dexamethasone (MeziKD) Versus Carfilzomib and Dexamethasone (Kd) in Participants W
A phase 3 trial of Mezigdomide, Carfilzomib, Dexamethasone in multiple myeloma, run by Bristol-Myers Squibb, active and no longer recruiting.
Overview
A Study to Evaluate Mezigdomide in Combination With Carfilzomib and Dexamethasone (MeziKD) Versus Carfilzomib and Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma (SUCCESSOR-2) is a phase 3 interventional study registered as NCT05552976 by Bristol-Myers Squibb, with 606 participants enrolled, started 2023-01-10 and due to reach its primary completion in 2026-07-18. Interventions recorded: Mezigdomide, Carfilzomib, Dexamethasone. Conditions listed: Relapsed or Refractory Multiple Myeloma. No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialA Study to Determine the Recommended Dose and Schedule, and Evaluate the Safety and Preliminary Efficacy of Mezigdomide in Combination With Elranatama
Shares Mezigdomide, Dexamethasone, Bristol Myers Squibb, Multiple myeloma.
- TrialA Study to Determine the Recommended Dose and Regimen and to Evaluate the Safety and Preliminary Efficacy of CC-92480 in Combination With Standard Tre
Shares Mezigdomide, Carfilzomib, Dexamethasone, Bristol Myers Squibb.
- TrialA Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Re
Shares Mezigdomide, Dexamethasone, Bristol Myers Squibb, Multiple myeloma.
- TrialA Study to Evaluate Safety, Drug Levels and Effectiveness of CC-92480 (BMS-986348) in Combination With Other Treatments in Participants With Relapsed
Shares Mezigdomide, Dexamethasone, Bristol Myers Squibb, Multiple myeloma.
- TrialA Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Multiple Myeloma Receiving T Cell Engaging Bi/Tri-spe
Shares Mezigdomide, Carfilzomib, Dexamethasone, Multiple myeloma.
- TrialA Study to Determine Dose, Safety, Tolerability and Efficacy of CC-220 Monotherapy, and in Combination With Other Treatments in Subjects With Multiple
Shares Carfilzomib, Dexamethasone, Bristol Myers Squibb, Multiple myeloma.
- TrialStudy of Venetoclax in Combination With Carfilzomib and Dexamethasone in Participants With Relapsed or Refractory Multiple Myeloma (MM)
Shares Carfilzomib, Dexamethasone, Multiple myeloma.
- TrialA Study to Investigate Subcutaneous Isatuximab in Combination With Carfilzomib and Dexamethasone in Adult Participants With Relapsed and/or Refractory
Shares Carfilzomib, Dexamethasone, Multiple myeloma.